The FDA introduced the Commissioner’s National Priority Voucher (CNPV) pilot program aimed at expediting review times to one or two months for drugs aligning with critical U.S. health priorities. Priorities include addressing rare diseases, America’s chronic disease burden, public health crises, and newly added affordability goals. The pilot encourages domestic drug development and supply chain improvements. Eligible projects must meet criteria such as maintaining robust U.S. clinical trial enrollment or lowering drug prices consistent with Most Favored Nation standards. This program intends to support prompt access to medications critical for public health and cost reduction.